D-0650-2016 Class III Terminated
FDA drug recall D-0650-2016 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Jan 28, 2016 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification result for known impurity at 6 month timepoint. The recall status is terminated (terminated Dec 21, 2016). Affected quantity: 868 unit cartons (86,800 tablets).
Recall details
- Product Type
- Drugs
- Report Date
- Feb 10, 2016
- Initiation Date
- Jan 28, 2016
- Termination Date
- Dec 21, 2016
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 868 unit cartons (86,800 tablets)
Product description
Clonazepam Tablets, USP, 0.5 mg, 100-count carton, Rx only, Manufactured by Mylan Pharmaceuticals Inc., Morgantown, WV, 26505, NDC:51079-881-21
Reason for recall
Failed Impurities/Degradation Specifications: out of specification result for known impurity at 6 month timepoint.
Distribution pattern
Nationwide
Code information
Lot # 3063759, Exp.07/16
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0650-2016
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026